MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know | The Motley Fool
Focused on precision therapies for endocrine disorders, this biotech firm reported a notable insider buy amid a year of sharp stock gains.

Source: The Motley Fool
Focused on precision therapies for endocrine disorders, this biotech firm reported a notable insider buy amid a year of sharp stock gains.